Figure 6.
Prolongation of B cell survival is dependent on the treatment with rhTNFSF13 or its receptor blockers. Proportion of viable B cells according to treatment with TNFSF13 (A) or receptor blockers (B). *P<0.05.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.